Pro-Dex, Inc.

NASDAQ:PDEX

Medical - Instruments & Supplies

Healthcare
$63.94 +5.86%

+$3.54 today

Market cap
$204.61M
Beta
-0.00
P/E (TTM)
17.1
EPS (TTM)
$3.75
52W Low $23.47High $68.99

Volume 0.04M

Average 0.04M

PDEX Research & Development

Spending on developing new products, technologies, and improvements to existing offerings.

Pro-Dex, Inc.NASDAQ: PDEX

Research & Development · Q3 FY2026 · quarter ended Mar 2026

Research & development declines year over year

Q3 FY2026 research & development of $827K fell 12.7% year over year, behind the -9.4% change in trailing-twelve-month research & development. Sequentially, it rose 12.7% from the prior quarter. Over 3 fiscal years it compounded at +6.9% a year.

Context

  • Research & development amounted to 5.5% of revenue in FY2025, down 0.5 pp from a year earlier.
  • Research & development increased in 2 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from -12.7% toward the trailing-twelve-month pace of -9.4%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$827K+12.7% QoQ
Last fiscal yearJun 2025
$3.64M+14.0% YoY
LTMMar 2026
$3.23M-9.4% YoY
Research & Development past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-12.7%——
1 year+14.0%——
3-year CAGR+6.9%——
5-year CAGR——
10-year CAGR——

Research & Development history

USD · from the income statement

Latest · FY2025
3.64M USD
Year-over-year change
+14.0%
4-year CAGR
+5.1%

Research & Development vs competitors

How PDEX compares with its peers on the latest reported figures

  • PDEX's LTM Mar 2026 research & development of $3.23M is the 8th highest of the 9 companies compared; the peer median is $9.49M.
  • Its year-over-year change of -9.4% is the 4th highest of 9, against a peer median of -11.0%.
  • Research & development amounts to 4.3% of revenue for PDEX, versus a peer median of 93.4%.
PDEX Competitors Peer median
Research & Development for PDEX and competitors
Company Period LTM YoY 3-year CAGR% of revenue
CGTXCognition Therapeutics, Inc.LTM Mar 2026$32.45M -22.6%+7.0%—
GLSIGreenwich LifeSciences, Inc.LTM Mar 2026$15.76M +21.0%+38.5%—
RPIDRapid Micro Biosystems, Inc.LTM Mar 2026$13.34M -7.2%+1.9%38.8%
SERASera Prognostics, Inc.LTM Mar 2026$12.87M -10.5%-2.6%22573.7%
MBOTMicrobot Medical Inc.LTM Mar 2026$6.11M -11.4%-6.7%5814.3%
LUCDLucid Diagnostics Inc.LTM Mar 2026$5.46M -7.8%+691.2%106.3%
APYXApyx Medical CorporationLTM Mar 2026$3.33M -25.7%-9.5%6.0%
PDEXPro-Dex, Inc.LTM Mar 2026$3.23M -9.4%+6.9%4.3%
STSSSkyAI, Inc.LTM Mar 2026$319.38K -20.4%-50.4%80.5%
Peer median (excluding PDEX) $9.49M-11.0%-0.4%93.4%

Competitors are the stored peer set for PDEX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Jun 2021
FY2022
Jun 2022
FY2023
Jun 2023
FY2024
Jun 2024
FY2025
Jun 2025
Revenue42.04M42.04M46.09M53.84M66.59M
Cost of Revenue28.91M28.91M33.34M39.29M47.08M
Gross Profit13.13M13.13M12.75M14.55M19.51M
Gross Margin31.2%31.2%27.7%27.0%29.3%
Research & Development2.98M2.98M2.8M3.19M3.64M
Selling, General & Admin4.99M4.99M4.18M4.19M5.19M
Operating Expenses8.01M8.01M6.99M7.38M8.82M
Depreciation & Amortization726K726K857K1.16M1.24M
EBITDA6.88M6.88M10.82M4.35M14.13M
EBITDA Margin16.4%16.4%23.5%8.1%21.2%
Operating Income5.12M5.12M5.76M7.17M10.69M
Operating Margin12.2%12.2%12.5%13.3%16.1%
Interest Income126K76K294K144K82K
Interest Expense352K464K533K558K829K
Other Income / Expenses571K571K3.67M(4.54M)1.37M
Income Before Tax5.69M5.69M9.43M2.63M12.06M
Pre-Tax Margin13.5%13.5%20.5%4.9%18.1%
Income Tax Expense1.12M1.12M2.35M507K3.08M
Net Income4.57M4.57M7.07M2.13M8.98M
Net Margin10.9%10.9%15.3%4.0%13.5%
EPS (Basic)1.171.261.980.612.73
EPS (Diluted)1.131.211.950.602.67
Weighted Avg Shares3.8M3.64M3.57M3.5M3.29M
Weighted Avg Shares (Diluted)3.94M3.76M3.64M3.57M3.36M

Pro-Dex, Inc.

NASDAQ:PDEX

Intrinsic Alpha fair value

Locked

Current Price

$63.94

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.